Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Chest MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.N Engl J Med. 2019; 381: 1809-1819
- VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.N Engl J Med. 2018; 379: 1612-1620
- Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.Lancet. 2019; 394: 1940-1948
- Ivacaftor in a G551D homozygote with cystic fibrosis.N Engl J Med. 2013; 369: 1280-1282
- VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.N Engl J Med. 2018; 379: 1599-1611
- Tezacaftor-Ivacaftor in residual-function heterozygotes with cystic fibrosis.N Engl J Med. 2017; 377: 2024-2035
- Hart SL: new approaches to genetic therapies for cystic fibrosis.J Cyst Fibros. 2020; 19: S54-S59
- Delivering on the promise of gene editing for cystic fibrosis.Genes Dis. 2019; 6: 97-108
- Gene and base editing as a therapeutic option for cystic fibrosis-learning from other diseases.Genes (Basel). 2019; 10: 387
- Emerging therapeutic approaches for cystic fibrosis. From gene editing to personalized medicine.Front Pharmacol. 2019; 10: 121
- Nucleic acid therapies for cystic fibrosis.Nucleic Acid Ther. 2018; 28: 1-9
- Cystic fibrosis gene therapy: a mutation-independent treatment.Curr Opin Pulm Med. 2016; 22: 602-609
- A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion.Nat Commun. 2021; 12: 4358
- The efficiency of nonsense-mediated mRNA decay is an inherent character and varies among different cells.Eur J Hum Genet. 2007; 15: 1156-1162
- Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin.J Clin Invest. 2007; 117: 683-692
- Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations.Nat Med. 1996; 2: 467-469
- Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations.N Engl J Med. 2003; 349: 1433-1441
- Safety, tolerability, and pharmacokinetics of single ascending doses of ELX-02, a potential treatment for genetic disorders caused by nonsense mutations, in healthy volunteers.Clin Pharmacol Drug Dev. 2019; 8: 984-994
- Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial.Lancet Respir Med. 2014; 2: 539-547
- Engineered transfer RNAs for suppression of premature termination codons.Nat Commun. 2019; 10: 822
- Evaluation of eluforsen, a novel RNA oligonucleotide for restoration of CFTR function in in vitro and murine models of p.Phe508del cystic fibrosis.PLoS One. 2019; 14: e0219182
- The cystic fibrosis-like airway surface layer is not a significant barrier for delivery of eluforsen to airway epithelial cells.J Aerosol Med Pulm Drug Deliv. 2019; 32: 303-316
- Antisense oligonucleotide eluforsen is safe and improves respiratory symptoms in F508DEL cystic fibrosis.J Cyst Fibros. 2020; 19: 99-107
- Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis.J Cyst Fibros. 2019; 18: 536-542
- The suppression of premature termination codons and the repair of splicing mutations in CFTR.Curr Opin Pharmacol. 2017; 34: 125-131
- The molecular basis of disease variability among cystic fibrosis patients carrying the 3849+10 kb C-->T mutation.Genomics. 1998; 53: 276-283
- Lipid nanoparticle-delivered chemically modified mRNA restores chloride secretion in cystic fibrosis.Mol Ther. 2018; 26: 2034-2046
- Safety and tolerability of a single dose of MRT5005, an inhaled CFTR MRNA therapeutic in adult CF patients.Pediatr Pulmonology. 2019; 54: 350
- Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans.Nature. 1994; 371: 802-806
- Gene therapy for cystic fibrosis using E1-deleted adenovirus: a phase I trial in the nasal cavity. The University of North Carolina at Chapel Hill.Hum Gene Ther. 1994; 5: 615-639
- Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis.Virology. 1996; 217: 11-22
- Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: biological efficacy study.Hum Gene Ther. 1993; 4: 759-769
- Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis.Cell. 1993; 75: 207-216
- Cystic fibrosis gene therapy using an adenovirus vector: in vivo safety and efficacy in nasal epithelium.Hum Gene Ther. 1994; 5: 209-219
- A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies.Hum Gene Ther. 2002; 13: 1349-1359
- A phase I/II study of tgAAV-CF for the treatment of chronic sinusitis in patients with cystic fibrosis.Hum Gene Ther. 1998; 9: 889-909
- A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis.Thorax. 2013; 68: 1075-1077
- Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial.Lancet Respir Med. 2015; 3: 684-691
- A phase I/IIa safety and efficacy study of Nebulized liposome-mediated gene therapy for cystic fibrosis supports a Multidose trial.Am J Respir Crit Care Med. 2015; 192: 1389-1392
- CAR T cell therapy for hematological malignancies.Curr Med Sci. 2019; 39: 874-882
- CAR T-cell cocktail therapy for B-cell malignancies.Lancet Oncol. 2019; 20: e669
- Gene therapy for beta-thalassemia: Updated perspectives.Appl Clin Genet. 2019; 12: 167-180
- First gene therapy for beta-thalassemia approved.Nat Biotechnol. 2019; 37: 1102-1103
- Gene therapy for beta thalassemia.Nat Med. 2018; 24: 1781
- Gene therapy for color blindness.N Engl J Med. 2009; 361: 2483-2484
- Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial.Lancet. 2016; 388: 661-672
- Gene therapy rescues newborns with spinal muscular atrophy.Nat Biotechnol. 2018; 36: 669-670
- Single-dose gene-replacement therapy for spinal muscular atrophy.N Engl J Med. 2017; 377: 1713-1722
- Gene therapy rescues disease phenotype in a spinal muscular atrophy with respiratory distress type 1 (SMARD1) mouse model.Sci Adv. 2015; 1: e1500078
- Personalized or precision medicine? The example of cystic fibrosis.Front Pharmacol. 2017; 8: 390
- Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients.Cell Stem Cell. 2013; 13: 653-658
- Vom hovel B, Weber WM, cathomen T: targeted Integration of a super-Exon into the CFTR locus leads to functional correction of a cystic fibrosis cell line model.PLoS One. 2016; 11: e0161072
- Correction of the DeltaF508 mutation in the cystic fibrosis transmembrane conductance regulator gene by zinc-finger nuclease homology-directed repair.Biores Open Access. 2012; 1: 99-108
- Highly efficient gene editing of cystic fibrosis patient-derived airway basal cells results in functional CFTR correction.Mol Ther. 2020; 28: 1684-1695
- Generation and genetic engineering of human induced pluripotent stem cells using designed zinc finger nucleases.Stem Cells Dev. 2013; 22: 595-610
- Targeted correction and restored function of the CFTR gene in cystic fibrosis induced pluripotent stem cells.Stem Cell Rep. 2015; 4: 569-577
- TALEN-mediated gene targeting for cystic fibrosis-gene therapy.Genes (Basel). 2019; 10: 39
- Peptide nucleic acids and gene editing: perspectives on structure and repair.Molecules. 2020; 25: 735
- Nanoparticles that deliver triplex-forming peptide nucleic acid molecules correct F508del CFTR in airway epithelium.Nat Commun. 2015; 6: 6952
- Poly(Lactic-co-Glycolic acid) nanoparticle delivery of peptide nucleic acids in vivo.Methods Mol Biol. 2020; 2105: 261-281
- Peptide nucleic acids as a tool for site-specific gene editing.Molecules. 2018; 23: 632
- New directions in pulmonary gene therapy.Hum Gene Ther. 2020; 31: 921-939
- Phase 1/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa.JCI Insight. 2019; 4: e130554
- Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa.JCI Insight. 2019; 4: e126243
- Gene therapy for epidermolysis bullosa.J Invest Dermatol. 2019; 139: 1221-1226
- Assessing human airway epithelial progenitor cells for cystic fibrosis cell therapy.Am J Respir Cell Mol Biol. 2020; 63: 374-385
- Challenges facing airway epithelial cell-based therapy for cystic fibrosis.Front Pharmacol. 2019; 10: 74
- The in vitro generation of lung and airway progenitor cells from human pluripotent stem cells.Nat Protoc. 2015; 10: 413-425
- Correction of airway stem cells: genome editing approaches for the treatment of cystic fibrosis.Hum Gene Ther. 2020; 31: 956-972
- High-efficiency, selection-free gene repair in airway stem cells from cystic fibrosis patients rescues CFTR function in differentiated epithelia.Cell Stem Cell. 2020; 26: 161-171.e4
- All-in-one dendrimer-based lipid nanoparticles enable precise HDR-mediated gene editing in.Vivo Adv Mater. 2021; 33: e2006619
- Tunability of biodegradable poly(amine- co-ester) polymers for customized nucleic acid delivery and other biomedical applications.Biomacromolecules. 2018; 19: 3861-3873
- Escaping the endosome: assessing cellular trafficking mechanisms of non-viral vehicles.J Control Release. 2021; 335: 465-480
- Debugging the genetic code: non-viral in vivo delivery of therapeutic genome editing technologies.Curr Opin Biomed Eng. 2018; 7: 24-32
- Polymeric vehicles for nucleic acid delivery.Adv Drug Deliv Rev. 2020; 156: 119-132
- A systematic study of Unsaturation in lipid nanoparticles leads to improved mRNA transfection in vivo.Angew Chem Int Ed Engl. 2021; 60: 5848-5853
- Testing thousands of nanoparticles in vivo using DNA barcodes.Curr Opin Biomed Eng. 2018; 7: 1-8
- Constrained nanoparticles deliver siRNA and sgRNA to T cells in vivo without targeting ligands.Adv Mater. 2019; 31: e1902251
- Advances in gene therapy for cystic fibrosis lung disease.Hum Mol Genet. 2019; 28: R88-R94
- On the corner of models and cure: gene editing in cystic fibrosis.Front Pharmacol. 2021; 12: 662110
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
